At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 224 enrolled
Drug / intervention
Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine +1 morebiological
Likely dose
Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine 0.5 mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety of a Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®) in Healthy Subjects Aged 9 Months to 55 Years in Vietnam
In Brief
A Phase 2 clinical trial evaluating Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine for Meningitis and 2 related conditions. Completed, enrolled 224 participants across 1 site.
Detailed Summary
The aim of the study is to assess the safety of Menactra vaccine in infants, toddlers, children, adolescents, and adults Objective: * To describe the safety profile after each and any dose (when applicable) of Menactra vaccine in participants aged 9 months to 55 years for registration.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesVietnam
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedDec 2015
Enrollment StartJun 2016
Primary CompletionDec 2016
TodayJul 2026
First PostedDec 29, 2015
Enrollment StartJun 6, 2016
Primary CompletionDec 5, 2016
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 10.5 years ago
Interventions
Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccinebiological
0.5 mL, Intramuscular. 2 doses 3 months apart
Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccinebiological
0.5 mL, Intramuscular.